Search results for "Prostate Cancer"
Task Force draft recommendation leaves PSA screening choice up to patients
Clinicians should talk to men ages 55 to 69 about the potential benefits and harms of screening, according to the U.S. Preventive Services Task Force. For men ages 70 years and older, the potential benefits of prostate-specific antigen (PSA)-based screening do not outweigh the harms, the Task Force said.
https://immattersacp.org/weekly/archives/2017/04/18/1.htm
18 Apr 2017
Leflunomide gets boxed warning, ARBs under review
Recalls, warnings, approvals and other regulatory news.
https://immattersacp.org/archives/2010/09/fda.htm
1 Sep 2010
Dealing with dementia, Q&As on COVID-19
This issue also covers testosterone and men's health, as well as preconception care.
https://immattersacp.org/archives/2020/05/dealing-with-dementia-qandas-on-covid-19.htm
1 May 2020
MKSAP Quiz: 2-year history of low libido
A 37-year-old man is evaluated for a 2-year history of low libido, loss of morning erections, fatigue, and decreasing muscle mass. His medical history is otherwise unremarkable. He takes no medications. A physical exam, lab studies, and pituitary MRI are done. Before starting therapy for this patient, what else should be determined?
https://immattersacp.org/weekly/archives/2017/05/09/3.htm
9 May 2017
Recalls expanded on defibrillators, infusion pumps
Recalls, warnings, approvals and other regulatory news.
https://immattersacp.org/archives/2010/07/fda.htm
1 Jul 2010
CONFERENCE COVERAGE Information plus documentation a must for informed ...
In 1990, Dr. Gottesman was sued forlate diagnosis of a patient’s prostate cancer.He won the case, and one of the jurors toldhim that the deciding factor had beeninformed consent ... documentation showingthat the patient had been warned that abiopsy could miss cancer.
https://immattersacp.org/archives/2012/01/acpi-201201-coding_t4.pdf
19 Dec 2011
Heparin labeling changed, non-egg flu vaccine approved
This regulatory update covers changed labeling for heparin and approval of a flu vaccine produced using cultured animal cells.
https://immattersacp.org/archives/2013/02/fda.htm
1 Feb 2013
Androgen-deprivation therapy associated with increased risk of cardiac mortality in men with cardiovascular problems
Androgen-deprivation therapy (ADT) for prostate cancer was associated with a 5% absolute excess risk of cardiac-specific mortality at 5 years in men with congestive heart failure or prior myocardial infarction, a study found.
https://immattersacp.org/weekly/archives/2014/11/04/6.htm
4 Nov 2014
Peanut butter recall issued, reminder for topical anesthetics
A summary of approvals, recalls, warnings and alerts.
https://immattersacp.org/archives/2009/03/fda.htm
1 Mar 2009
Clarification to a previous issue
In last week's ACP InternistWeekly, the first sentence of the item on reimbursement cuts and prostate drugs should have read “Medicare reimbursement cuts were associated with reduced use of androgen-deprivation therapy for prostate cancer, particularly among men for whom the benefits of such therapy were unclear.” The item has been updated.
https://immattersacp.org/weekly/archives/2010/11/16/8.htm
16 Nov 2010